Cargando…
Intracellular ABCB1 as a Possible Mechanism to Explain the Synergistic Effect of Hydroxychloroquine-Azithromycin Combination in COVID-19 Therapy
The co-administration of hydroxychloroquine with azithromycin is proposed in COVID-19 therapy. We hypothesize a new mechanism supporting the synergistic interaction between these drugs. Azithromycin is a substrate of ABCB1 (P-glycoprotein) which is localized in endosomes and lysosomes with a polariz...
Autor principal: | Scherrmann, JM. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7291928/ https://www.ncbi.nlm.nih.gov/pubmed/32533263 http://dx.doi.org/10.1208/s12248-020-00465-w |
Ejemplares similares
-
Hydroxychloroquine and azithromycin as potential treatments for COVID-19; clinical status impacts the outcome
por: Okour, Malek, et al.
Publicado: (2020) -
Effect of Combination Therapy of Hydroxychloroquine and Azithromycin on Mortality in Patients With COVID‐19
por: Lauriola, Marinella, et al.
Publicado: (2020) -
Effects of cardiac toxicity of combination therapy with hydroxychloroquine and azithromycin in COVID-19 patients
por: Yendrapalli, Usha, et al.
Publicado: (2021) -
In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect
por: Andreani, Julien, et al.
Publicado: (2020) -
Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19
por: Arshad, Samia, et al.
Publicado: (2020)